Antimicrobial lipopeptides and their uses II
|
New-generation polymyxins that target multidrug-resistant Gram-negative bacteria. These novel lipopeptide antibiotics have demonstrated superior in vivo efficacy and toxicity overcurrent polymyxin antibiotics.
- Novel lipopeptide antibiotics that target multidrug-resistant Gram- negative bacteria
- Greater efficacy and significantly less nephrotoxicity in animal models than currently available Polymyxin B drugs and Colistin
- Potential for administration via intravenous, inhaled or topical routes
Multidrug-resistance MDR
Superbugs
Gram-negative bacteria
Antibiotics
Using their polymyxin drug discovery platform, researchers from the Monash Institute of Pharmaceutical Sciences have identified a series of proprietary Polymyxin analogues that are active against Gram-negative ‘superbugs’.
The Monash researchers have completed in vivo efficacy and toxicity evaluations of the lipopeptide antibiotics in mouse models. When compared with commercially available Polymyxin B and Colistin, the lipopeptide analogues demonstrate improved antibacterial efficacy (Figure 1) and significantly less nephrotoxicity.
Licensing
29/09/2016 00:00:00
PCT/AU2016/050915
NZ741027
Others
Monash University has extensive academic and industrial experience in medicinal chemistry, pharmacokinetics/ pharmacodynamics, and in vitro and in vivo evaluations of antibiotics. Monash seeks a partner to complete advanced IND-enabling preclinical assessment of its lead candidate lipopeptide and to undertake clinical development.
2015-054
Australia
